Search
Piboserod
go.drugbank.com/drugs/DB04873InvestigationalPiboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.
Enoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnEnoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.
Categories: Compounds used in a research, industrial, or household settingEdotecarin
go.drugbank.com/drugs/DB04882InvestigationalEdotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.
Darusentan
go.drugbank.com/drugs/DB04883InvestigationalDarusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.
Categories: Vascular Endothelial Growth Factor AXimelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.
Galiximab
go.drugbank.com/drugs/DB04901InvestigationalGaliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Amolimogene bepiplasmid
go.drugbank.com/drugs/DB04904InvestigationalAmolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.
Sitimagene ceradenovec
go.drugbank.com/drugs/DB04907ExperimentalSitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy
Oxibendazole
go.drugbank.com/drugs/DB04910ExperimentalVet approvedOxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.